EFG Asset Management Americas Corp. Trims Position in DexCom, Inc. (NASDAQ:DXCM)

EFG Asset Management Americas Corp. lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 20.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,701 shares of the medical device company’s stock after selling 682 shares during the period. EFG Asset Management Americas Corp.’s holdings in DexCom were worth $335,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of DXCM. Mirae Asset Global Investments Co. Ltd. increased its position in shares of DexCom by 31.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock worth $138,643,000 after purchasing an additional 65,516 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of DexCom by 3,596.7% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock worth $567,000 after purchasing an additional 1,079 shares during the last quarter. West Family Investments Inc. acquired a new stake in shares of DexCom during the 1st quarter worth about $209,000. Ergoteles LLC increased its position in shares of DexCom by 60.6% during the 1st quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock worth $860,000 after purchasing an additional 634 shares during the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of DexCom by 26.4% during the 1st quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock worth $15,100,000 after purchasing an additional 6,160 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $132.00 on Monday. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00. The company has a market cap of $50.89 billion, a PE ratio of 99.78, a P/E/G ratio of 2.25 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The business has a 50-day simple moving average of $129.55 and a 200-day simple moving average of $117.04.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the company posted $0.34 earnings per share. The business’s revenue for the quarter was up 26.9% on a year-over-year basis. On average, equities research analysts forecast that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Insiders sold a total of 189,375 shares of company stock worth $25,530,859 over the last 90 days. 0.41% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Raymond James raised their price objective on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. UBS Group raised their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. Citigroup lifted their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $141.40.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.